2024
|
Invention
|
Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders. The disclosure t... |
2023
|
Invention
|
Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other s... |
|
Invention
|
Ganaxolone for use in treatment of status epilepticus.
This invention relates to methods for tre... |
|
Invention
|
Amorphous solid dispersion ganaxolone formulation.
This disclosure relates to a solid pharmaceut... |
|
P/S
|
Educational programming series, namely, providing panel discussions, presentation of seminars and... |
|
Invention
|
Prodrugs of ganaxolone. This disclosure relates to ganaxolone derivatives, as well as methods of ... |
2022
|
Invention
|
Amorphous solid dispersion ganaxolone formulation. This disclosure relates to a solid pharmaceuti... |
|
Invention
|
Ganaxolone for use in treatment of established status epilepticus. This invention relates to meth... |
|
P/S
|
Pharmaceutical preparations for the treatment of seizures and epilepsy, status epilepticus, epile... |
|
P/S
|
Pharmaceutical preparations for the treatment of seizures
and epilepsy, status epilepticus, epil... |
|
Invention
|
Ganaxolone for use in treating genetic epileptic disorders.
The disclosure provides a method of ... |
|
P/S
|
Administration of a discount program for enabling participating patients to obtain discounts on c... |
2021
|
Invention
|
Use of ganaxolone in treating an epilepsy disorder. The disclosure to methods for treating seizur... |
|
P/S
|
pharmaceutical preparations for the treatment of seizures and epilepsy, status epilepticus, epile... |
|
Invention
|
Ganaxolone for use in treatment of super refractory status epilepticus. This invention relates to... |
|
P/S
|
Pharmaceutical preparations for the treatment of seizures and epilepsy, status epilepticus, encep... |
|
P/S
|
Pharmaceutical preparations for the treatment of seizures
and epilepsy, status epilepticus, ence... |
|
P/S
|
Pharmaceutical preparations for the treatment of epilepsy,
epileptic encephalopathies, seizures,... |
|
P/S
|
Pharmaceutical preparations for the treatment of epilepsy, epileptic encephalopathies, seizures, ... |
2020
|
Invention
|
Ganaxolone for use in treating tuberous sclerosis complex. The disclosure to methods for treating... |
|
Invention
|
Injectable neurosteroid formulations containing nanoparticles.
The disclosure provides an inject... |
|
Invention
|
Ganaxolone for use in treatment of status epilepticus. This invention relates to methods for trea... |
|
P/S
|
pharmaceutical preparations for the treatment of epilepsy, epileptic encephalopathies, seizures, ... |
2019
|
Invention
|
Ganaxolone for use in prophylaxis and treatment of pospartum depression. Uses of ganaxolone in pr... |
2018
|
Invention
|
Ganaxolone for use in treating genetic epileptic disorders. The disclosure provides a method of t... |
|
Invention
|
Compositions and methods for treating autism spectrum disorder.
A method of treating suffering f... |
|
Invention
|
Sustained release injectable neurosteroid formulations. The disclosure provides a sustained relea... |
|
Invention
|
Sustained release injectable neurosteroid formulations.
The disclosure provides a sustained rele... |
2017
|
Invention
|
Method of administering a neurosteroid to effect electroencephalographic (eeg) burst suppression.... |
2016
|
Invention
|
Injectable neurosteroid formulations containing nanoparticles. The disclosure provides an injecta... |
|
Invention
|
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizur... |
2010
|
Invention
|
Method for making 3.alpha.-hydroxy, 3.beta.- methyl-5.alpha.-pregnan-20-one (ganaxolone). Applica... |
|
Invention
|
Method for making 3α-hydroxy, 3β- methyl-5α-pregnan-20-one (ganaxolone). Applicants have discover... |
2007
|
Invention
|
Pseudobase benzo [c] phenanthridines with improved efficacy, stability, and safety. Pseudobase be... |
2005
|
Invention
|
Method and system for screening compounds for muscular and/or neurological activity in animals. S... |